Recombinant Human Frizzled-10 Fc Chimera Protein, CF

• Reactivity: Hu
• Applications: Binding Activity
• Format: Carrier-Free

Recombinant Human Frizzled-10 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to bind biotinylated recombinant mouse Wnt-3a in a functional ELISA with an estimated K_d <5 nM.
• Source: Mouse myeloma cell line, NS0-derived human Frizzled-10 protein
  

  Human Frizzled-10 (Ile21-Gly161) Accession # Q6NSL8	IEGRMD	IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: Q6NSL8
• N-terminal Sequence: Ile21
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: FZD10
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Binding Activity
• Theoretical MW: 43 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 56-58 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Frizzled-10 Fc Chimera Protein, CF

• CD350 antigen
• CD350
• frizzled (Drosophila) homolog 10
• frizzled homolog 10 (Drosophila)
• Frizzled10
• Frizzled-10
• Fz10
• FZ-10
• FZD10
• FzE7
• hFz10

Background

Frizzled-10, also known as CD350, is a 68 kDa seven pass transmembrane glycoprotein in the Frizzled family of Wnt receptors (1, 2). The 205 amino acid N-terminal extracellular region of Frizzled-10 contains a cysteine-rich domain that comprises the Wnt binding domain and mediates receptor oligomerization (3‑5). The C-terminal cytoplasmic tail contains a PDZ-interaction motif (3). PDZ motifs mediate intracellular binding to scaffolding proteins. Within the cysteine-rich domain, human Frizzled‑10 shares 71% amino acid (aa) sequence identity with Frizzled-9 and 31%-46% with Frizzled-1, -2, -3, -4, -5, - 6, -7, and -8. It shares 96%, 94%, 90%, and 82% aa sequence identity with chick, mouse, Xenopus, and zebrafish Frizzled-10, respectively. Frizzled-10 is expressed during embryogenesis in the primitive streak, dorsal neural tube, developing brain, limb bud, and airway epithelium (6-11). It is induced by Shh and colocalizes with Shh and Wnt-7a in the neural tube (12, 13). In the adult, Frizzled-10 is expressed in placenta, gastric glands, and colon and renal tubule epithelial cells (4). Frizzled-10 associates with LRP5 to transduce Wnt-7a and Wnt-7b signals, resulting in the stabilization of cytoplasmic beta-catenin (11, 13). Frizzled-10 is also up-regulated in some cancers and transformed cell lines (4, 14). It binds hypoxia inducible gene 2, which promotes oncogenic Wnt signaling and functions as an autocrine growth factor for renal cell carcinomas (15).

1. Kikuchi, A. et al. (2007) Cell. Signal. 19:659.
2. Wang, H. et al. (2006) Cell. Signal. 18:934.
3. Koike, J. et al. (1999) Biochem. Biophys. Res. Commun. 262:39.
4. Nagayama, S. et al. (2005) Oncogene 24:6201.
5. Dann, C.E. et al. (2001) Nature 412:86.
6. Kemp, C.R. et al. (2007) Dev. Dyn. 236:2011.
7. Kawakami, Y. et al. (2000) Mech. Dev. 91:375.
8. Nasevicius, A. et al. (2000) Mech. Dev. 92:311.
9. Moriwaki, J. et al. (2000) Biochem. Biophys. Res. Commun. 278:377.
10. Stark, M.R. et al. (2000) Mech. Dev. 93:195.
11. Wang, Z. et al. (2005) Mol. Cell. Biol. 25:5022.
12. Nunnally, A.P. and B.A. Parr (2004) Dev. Genes Evol. 214:144.
13. Kawakami, Y. et al. (2000) Dev. Growth Differ. 42:561.
14. Saitoh, T. et al. (2002) Int. J. Oncol. 20:117.
15. Togashi, A. et al. (2005) Cancer Res. 65:4817.

Publications for Frizzled-10 (3459-FZ)(2)

Publications using 3459-FZ

• R Chidiac, M Abedin, G Macleod, A Yang, PE Thibeault, LL Blazer, JJ Adams, L Zhang, H Roehrich, HN Jo, S Seshagiri, SS Sidhu, HJ Junge, S Angers A Norrin/Wnt surrogate antibody stimulates endothelial cell barrier function and rescues retinopathy Embo Molecular Medicine, 2021-06-09;0(0):e13977. 2021-06-09 [PMID: 34105895] (Bioassay, Human)
• Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature, 2012-07-26;487(7408):505-9. 2012-07-26 [PMID: 22763448] (Bioassay, Human)

Bioinformatics

• Gene Symbol: FZD10
• Uniprot:
  • Q6NSL8()